CompletedNCT05658510
Dexmedetomidine for agitation in bipolarity and schizophrenia
About this title
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
Read the official source — NCT05658510Medication studyAges 18–75United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
- Listed locations
- Bellflower and 23 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: November 21, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 452
- Sponsor
- BioXcel Therapeutics Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT05658510
- Official title
Show the full official title
Efficacy And Safety of BXCL501 Evaluated For At-Home Use In A Multisite Double-Blind Placebo-Controlled Trial For Agitation Associated With Schizophrenia And Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bellflower · Cerritos · Culver City
19 more locations
- Garden Grove
- Lemon Grove
- Los Angeles
- Oceanside
- Orange
- Rancho Cucamonga
- Riverside
- Denver
- Miami
- Elgin
- Gaithersburg
- Las Vegas
- Berlin
- Beachwood
- Austin
- DeSoto
- Irving
- Plano
- Everett
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is BioXcel Therapeutics Inc.
Did this study involve medication?
Yes. The study involved medication, including BXCL501 and Matching Placebo.
Who was this study for?
Listed age limits: 18 years to 75 years.
